Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
2005
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2005
Report date:
2005

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
Deviations:
no
GLP compliance:
yes
Test type:
acute toxic class method

Test material

Constituent 1
Chemical structure
Reference substance name:
7-But-2-ynyl-8-[(R)-3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-piperidin-1-yl]-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro- purine-2,6-dione
EC Number:
937-756-4
Cas Number:
886588-63-2
Molecular formula:
C33 H30 N8 O4
IUPAC Name:
7-But-2-ynyl-8-[(R)-3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-piperidin-1-yl]-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro- purine-2,6-dione

Test animals

Species:
rat
Strain:
other: CrlGlxBrlHan:WI
Sex:
male/female

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
other: 0.5% aqueous hydroxyethylcellulose
Doses:
200 and 2000 mg/kg
No. of animals per sex per dose:
3 female at 200mg/kg
3 male and 3 female at 2000mg/kg
Control animals:
no

Results and discussion

Effect levels
Sex:
male/female
Dose descriptor:
approximate LD50
Effect level:
> 2 000 mg/kg bw
Based on:
test mat.
Mortality:
No mortality was observed subsequent to a single oral administration of 200 mg/kg and
2000 mg/kg, respectively rats.
Clinical signs:
From as early as 0.25 h to 3.5 h post administration at the latest, piloerection was noted at
all doses in rats of both genders. The animals returned to normal during the Day 1 (6.25 h
post administration at the latest) and no further abnormal clinical signs were observed
throughout the entire 14-day observation period.
Body weight:
No effects on body weight development were noted in males and females
Gross pathology:
No necropsy findings were noted in females treated with 200 mg/kg, as well as in rats of
both genders subsequent to administration of 2000 mg/kg

Applicant's summary and conclusion

Interpretation of results:
other: "not classified" according CLP
Conclusions:
Under the conditions of the present study, no mortality occurred in rats subsequent to a single oral administration of CD 749 BS by
gavage at doses of 200 mg/kg and 2000 mg/kg, respectively.
The approximate lethal dose (ALD) for CD 749 BS is above 2000 mg/kg for male and female rats.